Who Owns Zofran?
Zofran is owned by Sandoz Group AG (SIX: SDZ), the Swiss generics and biosimilars company spun off from Novartis in October 2023. Sandoz Inc., based in Princeton, New Jersey, holds the US new drug applications for Zofran tablets, oral solution, and Zofran ODT. GlaxoSmithKline originally developed the drug, and Novartis acquired US rights in March 2015.
Parent Company
Acquired
2023
Status
Publicly Traded
Headquarters
Zofran Timeline
United StatesOfficial Website
Who Owns Zofran?
- Parent Company: Sandoz Group AG
- Ownership Type: Wholly owned
- Acquisition Year: 2023
- Company Type: Publicly Traded
- Stock Ticker: SIX Swiss Exchange: SDZ
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Zofran | Sandoz Group AG | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Zofran on AmazonAdvertisement
History of Zofran
- Founded: 1991
- Founders: Glaxo (developer)
- Acquired by Sandoz Group AG: 2023
Zofran's story begins in Glaxo's UK laboratories in the early 1980s, when researchers working on serotonin pharmacology identified ondansetron as a potent blocker of the 5-HT3 receptor. That receptor, concentrated in the gut and brainstem's vomiting center, was newly implicated in the severe nausea caused by chemotherapy. The FDA approved Zofran injection in January 1991 and oral forms followed, and the drug effectively created the modern antiemetic class.
For cancer patients the impact was immediate. Before 5-HT3 antagonists, chemotherapy-induced vomiting was one of the most feared and least controllable aspects of treatment; ondansetron turned it into a manageable side effect for most patients. Zofran became a blockbuster and one of the products that powered Glaxo's rise through the 1990s, with global sales peaking around $1.6 billion before generic erosion.
Competitors followed in the same class, including granisetron (Kytril), dolasetron (Anzemet), and later palonosetron (Aloxi), but Zofran remained the reference brand. Patent protection in the US lapsed in the mid-2000s, and generic ondansetron captured the overwhelming majority of prescriptions within a few years.
In 2014 and 2015 Novartis and GSK executed a multi-part transaction in which Novartis acquired GSK's marketed oncology portfolio. The transfer became effective March 2, 2015, moving US Zofran rights to Novartis Pharmaceuticals Corporation. That ownership lasted until October 2023, when Novartis completed the spin-off of Sandoz, its generics and biosimilars division, as a separately listed Swiss company. The Zofran NDAs moved to Sandoz, which now maintains the brand's US labeling and regulatory file. A 2025 FDA approval letter for updated prescribing information was directed to Sandoz Inc., confirming the current holder.
Advertisement
About Sandoz Group AG
What does Sandoz Group own?
Sandoz Group owns the Sandoz brand for generic medicines and biosimilars. The company markets approximately 1,300 generic medicines worldwide and has a pipeline of more than 400. Key biosimilar products include Pyzchiva, Binocrit, Hyrimoz, Omnitrope, Wyost and Jubbonti, Afqlir, and Tyruko. The company also operates manufacturing facilities and distribution centers globally.
Is Sandoz Group publicly traded?
Yes, Sandoz Group AG is publicly traded on the SIX Swiss Exchange under ticker SDZ. The company began trading independently in October 2023 following its spinoff from Novartis.
Who founded Sandoz Group?
Sandoz Group was established in 2003 as the generics division of Novartis. The company became independent through a spinoff from Novartis in October 2023. The Sandoz name traces its heritage back to 1886, when the original Sandoz chemical company was founded in Basel, Switzerland.
Where is Sandoz Group headquartered?
Sandoz Group is headquartered in Basel, Switzerland. The company relocated its corporate headquarters from Risch to Basel in April 2025. The registered office is at Centralbahnstrasse 4, 4051 Basel.
Advertisement
How many brands does Sandoz Group own?
Sandoz Group owns one main brand: Sandoz, for generic medicines and biosimilars. The brand includes approximately 1,300 generic medicines and a growing portfolio of biosimilars.
Who owns Sandoz Group?
Sandoz Group is a publicly traded company with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. Novartis does not retain a significant stake following the spinoff. Gilbert Ghostine serves as Chairman of the Board of Directors.
What is Sandoz Group's revenue?
Sandoz Group reported FY2025 net sales of USD 11.1 billion, up 5 percent at constant currencies and 7 percent in USD. Core EBITDA was USD 2.4 billion with a margin of 21.7 percent. The company's 2026 guidance projects mid to high single-digit net sales growth at constant currencies.
Who is the CEO of Sandoz Group?
Richard Saynor serves as Chief Executive Officer of Sandoz Group AG. Remco Steenbergen serves as Chief Financial Officer. Gilbert Ghostine serves as Chairman of the Board of Directors.
Advertisement
- Founded: 2003
- Headquarters: Basel, Switzerland
- Company Type: Publicly Traded
- Stock: SIX Swiss Exchange: SDZ
- Revenue: USD 11.1 billion (FY2025)
- Employees: Approximately 22,356
Where Is Zofran Made / Based?
- Headquarters: Princeton, New Jersey, USA
- Manufacturing / Operations: Global
Zofran Categories & Tags
Zofran Recalls & Controversies
Zofran carries two significant controversy threads, both predating Sandoz's ownership.
First, safety. In 2012 the FDA restricted the 32 mg intravenous dose because of QT-interval prolongation and the associated risk of the potentially fatal arrhythmia torsades de pointes. The single high IV dose was withdrawn, and warnings about cardiac risk and electrolyte monitoring were added to the label.
Second, pregnancy litigation. Zofran was widely used off-label for morning sickness despite never being approved for that use. Hundreds of lawsuits alleged the drug caused birth defects and that GSK had promoted it in pregnancy without adequate evidence. GSK contested the claims, pointing to epidemiological data, and most of the consolidated litigation did not produce findings of liability against the company; courts in the MDL and related proceedings largely rejected the birth-defect claims, and regulatory agencies did not conclude the drug causes defects. The episode remains a standard case study in off-label prescribing risk.
Neither matter stems from Sandoz's stewardship, which began only in 2023. The current label reflects the accumulated safety record of thirty-plus years of use.
Advertisement
Brands Owned by Sandoz Group AG
Zofran Ownership: Pros & Cons
Advantages
- +Held by the global generics leader with deep US regulatory capability
- +Brand name retains strong prescriber and patient recognition
- +Manufacturing and distribution scale of Sandoz ensures supply continuity
- +Three decades of established safety data
Considerations
- -Generic ondansetron, including Sandoz's own, captures nearly all volume
- -Historical GSK-era litigation clouded the brand's reputation
- -Cardiac warnings limit dosing flexibility
- -No growth investment case for an off-patent reference brand
Advertisement
Frequently Asked Questions About Zofran
Sources & Further Reading
- Sandoz Group
- FDA Approval Letter to Sandoz Inc. (2025)
- DailyMed Zofran Labels
- Novartis-GSK Transaction History
- Sandoz Company Profile - /companies/sandoz-group
Advertisement
Competitors to Zofran
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Merck | USA | 2003 | Generic available | Global | All-ages | |
| Bristol Myers Squibb | USA | 1989 | Mass market | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsEmend
Owned by Merck & Co.
Prescription antiemetic medication (aprepitant) for preventing chemotherapy-induced nausea and vomiting, owned by Merck & Co. (NYSE: MRK). FDA approved in 2003. U.S. patent expired in 2019 with generic versions available.
antiemeticnauseavomiting
Healthcare PharmaceuticalsCarboplatin
Owned by Bristol Myers Squibb Company
Generic platinum-based chemotherapy drug originally marketed as Paraplatin by Bristol-Myers Squibb and now produced by dozens of manufacturers worldwide.
chemotherapyoncologyplatinum
Competitive Analysis
Market Positioning: Zofran competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Zofran
Looking for brands with different ownership structures? These similar brands are not owned by Sandoz Group AG, giving you alternative choices that support different corporate structures.
Healthcare Pharmaceuticals23andMe
Owned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
genetic-testingdna-kitsconsumer-genomics
Privately Owned
23andMe is privately owned, unlike Zofran which is under a publicly traded parent company.
Healthcare PharmaceuticalsAdcock Ingram
Owned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
pharmaceuticalsotchealthcare
Privately Owned
Adcock Ingram is privately owned, unlike Zofran which is under a publicly traded parent company.
Healthcare PharmaceuticalsArthrex
Owned by Arthrex Inc.
Orthopedic device brand of privately held Arthrex Inc., specializing in arthroscopic surgery products sold in more than 100 countries.
orthopedic-devicesarthroscopysports-medicine
Privately Owned
Arthrex is privately owned, unlike Zofran which is under a publicly traded parent company.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Zofran which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Zofran which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Zofran which is under a publicly traded parent company.
Sandoz Group AG Stock Information
Advertisement
Jobs at Sandoz Group AG
Latest News About Zofran
Advertisement
Related Articles About Zofran
View more articles
Health
Generic vs Brand Name Drugs: Same Company or Different
Teva is the world's largest generic drugmaker (~6% US share). Sandoz was spun off Novartis in 2023. Viatris came from Mylan + Pfizer's Upjohn. Pfizer itself holds hundreds of ANDAs. Explore our database.
Who Brands StaffOct 30, 2026
Generic DrugsBrand NamePharmaceuticals
Health
Hospital and Clinic Brand Ownership
HCA Healthcare is the largest for-profit hospital system (190 hospitals, $75.6B revenue). Tenet has 50 hospitals ($21.3B). UHS has 346 behavioral facilities. Fresenius leads dialysis. Explore our database.
Who Brands StaffNov 14, 2026
Hca HealthcareTenet HealthUhs
Health
Eye Care Brand Ownership: Bausch & Lomb to Alcon
J&J Vision (Acuvue) leads contact lenses at 27-30%. Alcon (Novartis spin-off) holds 25-27%. CooperVision has 22-24%. Bausch + Lomb has 12-15%. EssilorLuxottica dominates lenses at 30.7%. Explore our database.
Who Brands StaffNov 13, 2026
Bausch LombAlconCoopervision
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandgenetic-testing
23andMe
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
Brand in Healthcare & Pharmaceuticals
dna-kitsconsumer-genomics
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care